Uniform MSC Preparations for Stable Clinical-Scale Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The heterogeneity and variability of mesenchymal stem cell (MSC) populations in existing preparations lead to inconsistent therapeutic effects, making it difficult to achieve reproducible and stable therapeutic actions, especially in clinical settings.
Innovation Solution
Development of a method to produce uniform MSC preparations with a stable phenotype, characterized by specific antigen profiles (95% CD105+ and 95% CD166+, low CD45+), high TNFRI expression, and resilience to cryopreservation, allowing expansion to clinical scale with consistent therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MSC preparation methods are used, then MSC populations can be obtained, but the heterogeneity and variability of MSC populations lead to inconsistent therapeutic effects
Solution Approach 1:
The patent segments the heterogeneous MSC population by applying multiple selection criteria (surface marker expression profiles, differentiation capacity, proliferation rate) to isolate and enrich for specific MSC subsets with consistent therapeutic properties, thereby resolving the heterogeneity issue
Solution Approach 2:
The patent changes the selection parameters for MSC preparation by defining specific surface marker expression thresholds (e.g., CD73+, CD90+, CD105+ for human MSCs) and functional characteristics to standardize the MSC population and ensure consistent therapeutic effects across preparations
2Quantity of substance
If MSC preparations are expanded to clinical scale, then sufficient cell doses can be obtained, but maintaining phenotypic stability and therapeutic potential becomes difficult
Solution Approach 1:
The patent performs preliminary characterization and selection of MSCs with optimal phenotypic markers and functional properties before expansion, ensuring that the starting population has the desired characteristics that will be maintained during clinical-scale cultivation
Solution Approach 2:
The patent implements quality control measures with feedback mechanisms to monitor phenotypic stability during expansion, using surface marker analysis and functional assays to detect drift and adjust cultivation conditions to maintain therapeutic potential
3Ease of manufacture
If MSC preparations undergo cryopreservation, then storage and transport are enabled, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent applies cryoprotectant agents (such as DMSO or glycerol) before freezing to cushion the cellular structures against ice crystal formation and mechanical damage, thereby preserving membrane integrity and therapeutic function after freeze-thaw cycles
Data Source
AI summary
The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.